ArticlePloS one2025
In vitro study of probiotic Lactobacillus helveticus: Antibacterial effects on Porphyromonas gingivalis.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative inhibition of oral pathogens, biofilm formation, and inflammation-related responses by postbiotics fromJournal of oral microbiology · 2026Article
- Clinical and Microbiological Changes Following Multi-Strain Probiotic Mouthrinse Use in Dental Students with Halitosis: A Prospective Single-Arm Study.Clinical, cosmetic and investigational dentistry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Probiotics are gaining attention for their benefits as a supplement to improve oral health. This study aimed to evaluate the antibacterial effect of the probiotic Lactobacillus helveticus against Porphyromonas gingivalis, a significant pathogen in periodontal diseases. Antibacterial susceptibility was assessed using the well diffusion assay, with 0.12% chlorhexidine (CHX) served as the positive control. Biofilm biomass was evaluated using crystal violet staining. Cell viability in P. gingivalis treated with L. helveticus was determined using the LIVE/DEAD Baclight bacterial assay via fluorescence microscopy. Ultra-morphological alterations in these cells were further examined using Field Emission Scanning Electron Microscopy. The results indicated that L. helveticus significantly reduced the growth of P. gingivalis. The highest concentration of 109 cells/mL achieved the most substantial inhibition in the well diffusion assay, followed by concentrations of 108 cells/mL and 107 cells/mL, which demonstrated a clear dose-dependent response. Furthermore, biofilms of P. gingivalis treated with L. helveticus exhibited a notable biomass reduction of up to 85% at the highest concentrations. LIVE/DEAD staining confirmed a decreased in cell viability among the treated populations, while FESEM analysis revealed morphological disruptions in P. gingivalis cells treated with L. helveticus. These findings suggest that L. helveticus has a potent antibacterial effect against P. gingivalis, highlighting the need for further research to identify the optimal probiotic strategies that could enhance periodontal health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.